| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA662: Durvalumab in combination for untreated extensive stage small-cell lung cancer |
|
Medicine details |
|
| Medicine name | durvalumab (Imfinzi®) |
| Formulation | intravenous infusion |
| Reference number | 4680 |
| Indication | In combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC) |
| Company | AstraZeneca UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 11/09/2020 |
| NICE guidance | TA662: Durvalumab in combination for untreated extensive stage small-cell lung cancer |